KR20140063747A - 전염증성 상태를 치료 및 예방하기 위한 hdl-관련 분자의 용도 - Google Patents

전염증성 상태를 치료 및 예방하기 위한 hdl-관련 분자의 용도 Download PDF

Info

Publication number
KR20140063747A
KR20140063747A KR1020147008207A KR20147008207A KR20140063747A KR 20140063747 A KR20140063747 A KR 20140063747A KR 1020147008207 A KR1020147008207 A KR 1020147008207A KR 20147008207 A KR20147008207 A KR 20147008207A KR 20140063747 A KR20140063747 A KR 20140063747A
Authority
KR
South Korea
Prior art keywords
hdl
cells
apoa
hif
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147008207A
Other languages
English (en)
Korean (ko)
Inventor
로빈 파리아스-아이즈너
스리니바사 티. 레디
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20140063747A publication Critical patent/KR20140063747A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020147008207A 2011-08-29 2012-08-29 전염증성 상태를 치료 및 예방하기 위한 hdl-관련 분자의 용도 Withdrawn KR20140063747A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161528447P 2011-08-29 2011-08-29
US61/528,447 2011-08-29
US201261624333P 2012-04-15 2012-04-15
US61/624,333 2012-04-15
US201261646772P 2012-05-14 2012-05-14
US61/646,772 2012-05-14
PCT/US2012/052925 WO2013033260A1 (en) 2011-08-29 2012-08-29 Use of hdl-related molecules to treat and prevent proinflammatory conditions

Publications (1)

Publication Number Publication Date
KR20140063747A true KR20140063747A (ko) 2014-05-27

Family

ID=47756845

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147008207A Withdrawn KR20140063747A (ko) 2011-08-29 2012-08-29 전염증성 상태를 치료 및 예방하기 위한 hdl-관련 분자의 용도

Country Status (8)

Country Link
US (2) US9241976B2 (https=)
EP (1) EP2751126B1 (https=)
JP (1) JP6078067B2 (https=)
KR (1) KR20140063747A (https=)
CN (1) CN104039810A (https=)
AU (1) AU2012301955A1 (https=)
CA (1) CA2846865A1 (https=)
WO (1) WO2013033260A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426817B2 (en) 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
WO2018190896A1 (en) * 2017-04-13 2018-10-18 Lipimetix Development, Inc. Apoe mimetic peptide compositions
CN120085016A (zh) * 2025-03-14 2025-06-03 北京大学第三医院（北京大学第三临床医学院） 一种apoa1作为生物标志物在制备用于监测结肠炎症活动度的产品中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DK145385D0 (da) 1985-03-29 1985-04-01 Novo Industri As Monoklonalt antistof til immunkemisk analyse
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5114863A (en) 1986-09-30 1992-05-19 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Immunosorbant assay for α-1-antitrypsin, kit employing said assay, monoclonal antibody to α-1-antitrypsin, and hybridoma for producing said monoclonal antibody
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
SE8904007D0 (sv) 1989-11-28 1989-11-28 Ferring Ab Monoklona antikroppar och diagnostiseringsmetod
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
RU2152787C2 (ru) * 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
US20030027216A1 (en) 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
US5891641A (en) 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
US5955582A (en) 1997-09-26 1999-09-21 Beckman Coulter, Inc. Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20060068405A1 (en) 2004-01-27 2006-03-30 Alex Diber Methods and systems for annotating biomolecular sequences
US20050214760A1 (en) 2002-01-07 2005-09-29 Johns Hopkins University Biomarkers for detecting ovarian cancer
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
WO2004001010A2 (en) 2002-06-21 2003-12-31 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US7927791B2 (en) 2002-07-24 2011-04-19 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mRNA decay
NZ562192A (en) 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
CA2525385A1 (en) 2003-05-12 2004-11-25 The Children's Hospital Of Philadelphia Grp94-based compositions and methods of use thereof
EP1658497B1 (en) 2003-08-25 2008-12-03 Marc Ramael A method and kit for the quantitative and/or qualitative detection of components in a sample
WO2005065720A1 (en) 2004-01-09 2005-07-21 Mogam Biotechnology Research Institute Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same
WO2005093413A2 (en) 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US9487575B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
US7670792B2 (en) 2004-07-14 2010-03-02 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
US9488655B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
EP2848942B1 (en) 2004-07-14 2017-03-08 The Regents of The University of California Biomarkers for early detection of ovarian cancer
US7947645B2 (en) * 2004-09-02 2011-05-24 Cognosci, Inc. APO E analogs and methods for their use
US20060094039A1 (en) 2004-09-20 2006-05-04 Ron Rosenfeld Diagnosis of fetal aneuploidy
WO2006063132A2 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US7427662B2 (en) 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
AU2006223374B2 (en) 2005-03-11 2011-07-21 Aspira Women’s Health Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
KR20080007491A (ko) * 2005-04-29 2008-01-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 염증성 반응을 특징으로 하는 병리를 치료하기 위한 펩티드및 펩티드 모방체
US7604948B2 (en) 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
WO2007002069A2 (en) 2005-06-21 2007-01-04 Anthony Goncalves Serum biomarkers for breast cancer
US7575876B2 (en) 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders
WO2007068985A2 (en) 2005-12-16 2007-06-21 Electrophoretics Limited Diagnosis and prognosis of colorectal cancer
KR100725642B1 (ko) * 2006-01-20 2007-06-07 충남대학교산학협력단 저밀도 지단백질에 대해 항산화성을 갖는 펩타이드
US7723045B2 (en) 2006-02-10 2010-05-25 The Regents Of The University Of California Assays to predict atherosclerosis and dysfunctional high-density lipoprotein
AU2008266753A1 (en) * 2007-06-20 2008-12-24 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. ApoA-1 peptide mimetics
US8557767B2 (en) * 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) * 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
JP2009092440A (ja) 2007-10-04 2009-04-30 Shimadzu Corp 卵巣癌の診断システム及び卵巣癌の診断方法

Also Published As

Publication number Publication date
CN104039810A (zh) 2014-09-10
US20170204160A1 (en) 2017-07-20
JP2014526440A (ja) 2014-10-06
JP6078067B2 (ja) 2017-02-08
US20140323410A1 (en) 2014-10-30
CA2846865A1 (en) 2013-03-07
EP2751126A1 (en) 2014-07-09
US10208103B2 (en) 2019-02-19
WO2013033260A1 (en) 2013-03-07
AU2012301955A1 (en) 2014-03-06
EP2751126B1 (en) 2018-03-07
EP2751126A4 (en) 2015-11-04
US9241976B2 (en) 2016-01-26

Similar Documents

Publication Publication Date Title
JP5706818B2 (ja) ＡｐｏＥペプチドにより癌を治療する方法
US10889619B2 (en) Methods for treating cancer
JP2001502538A (ja) ミニｅ１ａ遺伝子及び遺伝子産物
US20150087598A1 (en) Treating muc1-expressing cancers with helicase inhibitors
US20150202248A1 (en) E2f as a target of hormone refractory prostate cancer
US10208103B2 (en) Use of HDL-related molecules to treat and prevent proinflammatory conditions
US9487575B2 (en) Compositions and methods for treatment of gynecologic cancers
ES2825078T3 (es) Tratamiento de enfermedades autoinmunitarias
CN118252913B (zh) 多肽偶联物及其在射血分数保留的心衰中的应用
WO2005004913A1 (ja) デコイを含む薬学的組成物およびその使用方法
KR20220051418A (ko) 근위축성 측삭 경화증 치료제
US20030162736A1 (en) Medicament comprising NK4 gene or recombinant NK4 protein
EP2582384B1 (en) Compositions and methods for treating cancer
KR20070011892A (ko) Ｍｓｘ1 단백질 또는 이를 코딩하는 유전자를유효성분으로 포함하는 세포사멸유도제
EP2510091A1 (en) Method and composition to increase radiation-induced tumor therapeutic effects
US20210322508A1 (en) Peptides and compositions for targeted treatment and imaging
US20240382561A1 (en) Glucoregulatory compound, composition and uses thereof
JP2006524712A (ja) カテプシンの阻害のための方法および組成物
CA3258422A1 (en) POLYTHERAPIES INCLUDING MYC MODULATION
WO2021223026A1 (en) Ezh1/2 knockdown peptides, methods and uses thereof
WO2012103163A2 (en) Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
HK1057376A (en) Medicament comprising nk4 gene of recombinant nk4 protein

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140327

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid